1. Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block

   • C. Busletta
   • E. Novo
   • M. Parola

   Editorial 23 July 2011 Pages: 299 - 305

2. MELD—good for many, not as good for others … at least for now

   • Thomas Schiano

   Editorial 25 July 2012 Pages: 306 - 308

3. The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease

   • Puneet Puri
   • Arun J. Sanyal

   Editorial 19 February 2013 Pages: 309 - 312

   

4. Noncirrhotic portal fibrosis: a rare cause of end-stage liver disease requiring liver transplantation

   • Sunil Taneja
   • Yogesh Chawla
   • Radha K. Dhiman

   Editorial 03 September 2011 Pages: 313 - 315

5. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management

   • Chun-Jen Liu
   • Pei-Jer Chen
   • Jia-Horng Kao

   Review Article 14 June 2011 Pages: 316 - 326

   

6. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection

   • Wai-Kay Seto
   • Man-Fung Yuen
   • Ching-Lung Lai

   Review Article 19 June 2011 Pages: 327 - 334

7. Autoimmune acute liver failure: an emerging etiology for intractable acute liver failure

   • Keiichi Fujiwara
   • Shin Yasui
   • Osamu Yokosuka

   Review Article 28 September 2012 Pages: 335 - 346

   

8. Model for End-Stage Liver Disease and liver cirrhosis-related complications

   • Luis Calzadilla Bertot
   • Eduardo Vilar Gomez
   • Luis Blanco Perez

   Review Article 10 October 2012 Pages: 347 - 355

9. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B

   • Yong-Peng Chen
   • Jie Peng
   • Jin-Lin Hou

   Review Article 17 May 2013 Pages: 356 - 368

   

10. Role of anticoagulant therapy in liver disease

    • Elisabeth P. C. Plompen
    • Jeoffrey N. L. Schouten
    • Harry L. A. Janssen

    Review Article 26 March 2013 Pages: 369 - 376

    

11. The risk factors and diagnosis of cholangiocarcinoma

    • Christopher A. Wadsworth
    • Adrian Lim
    • Shahid A. Khan

    Review Article 10 November 2012 Pages: 377 - 393

    

12. The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies

    • Liesbeth Ceelen
    • Marusya Lieveld
    • Mathieu Vinken

    Review Article 14 February 2013 Pages: 394 - 399

13. Nonalcoholic fatty liver disease following liver transplantation

    • Sanjaya Kumar Satapathy
    • Satheesh Nair
    • Jason M. Vanatta

    Review Article 26 April 2013 Pages: 400 - 412

    

14. Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?

    • Carmine Finelli
    • Giovanni Tarantino

    Review Article 26 October 2012 Pages: 413 - 428

    

15. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients

    • Teerha Piratvisuth
    • Patrick Marcellin
    • Zhi-Meng Lu

    Original Article 24 June 2011 Pages: 429 - 436

    

16. Current management and recommendations on hepatitis B therapy in HIV-coinfected patients

    • Lionel Piroth
    • Sophie Mahy
    • For the GERMIVIC Study Group

    Original Article 15 July 2011 Pages: 437 - 442

    

17. Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype

    • Wenpeng Li
    • Nadia Warner
    • Peter A. Revill

    Original Article 28 November 2012 Pages: 443 - 450

    

18. Are physicians following guidelines? A survey of Hepatitis B management strategies

    • Keat Hong Lee
    • Myat Oo Aung
    • Seng Gee Lim

    Original Article 06 October 2012 Pages: 451 - 459

    

19. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B

    • Bingliang Lin
    • Calvin Q. Pan
    • Zhiliang Gao

    Original Article 11 February 2013 Pages: 460 - 467

    

20. Clinicopathologic study on complications of orthotopic liver transplantation in 54 patients with chronic hepatitis B viral infection

    • Fei Pei
    • Kewei Shang
    • Jiangfeng You

    Original Article 07 February 2013 Pages: 468 - 476

    

21. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion

    • Chien-Hung Chen
    • Chuan-Mo Lee
    • Sheng-Nan Lu

    Original Article 21 June 2012 Pages: 477 - 488

    

22. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion

    • Shih-Cheng Yang
    • Sheng-Nan Lu
    • Chien-Hung Chen

    Original Article 22 June 2012 Pages: 489 - 499

    

23. Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries

    • Bilal Ahmed
    • Tooba Ali
    • Saeed Hamid

    Original Article 10 January 2013 Pages: 500 - 507

    

24. Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C

    • Shunsuke Sato
    • Takuya Genda
    • Takafumi Ichida

    Original Article 02 April 2011 Pages: 508 - 515

    

25. Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C

    • Said M. Hashemi
    • David van der Poorten
    • Jacob George

    Original Article 27 September 2012 Pages: 516 - 523

26. Inhibition of silent information regulator 1 induces glucose metabolism disorders of hepatocytes and enhances hepatitis C virus replication

    • Jian-Wu Yu
    • Li-Jie Sun
    • Bing-Zhu Yan

    Original Article 23 January 2013 Pages: 524 - 532

    

27. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection

    • Ayman A. Abdo
    • Mohammed N. Al-Ahdal
    • Ahmed Al-Qahtani

    Original Article Open access 08 February 2013 Pages: 533 - 538

    

28. B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease

    • Teruki Miyake
    • Masanori Abe
    • Morikazu Onji

    Original Article 09 February 2012 Pages: 539 - 547

    

29. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia

    • Seok-Chin Goh
    • Evelyn Lai-Ming Ho
    • Khean-Lee Goh

    Original Article 23 March 2012 Pages: 548 - 554

30. High alanine aminotransferase level as a predictor for the incidence of macrovascular disease in type 2 diabetic patients with fatty liver disease

    • Megumi Inoue
    • Junya Oribe
    • Hironobu Yoshimatsu

    Original Article 05 April 2012 Pages: 555 - 561

    

31. Maturation defective myeloid dendritic cells in nonalcoholic fatty liver disease patients release inflammatory cytokines in response to endotoxin

    • Deepa Rana
    • Ajay Duseja
    • Sunil K. Arora

    Original Article 06 May 2012 Pages: 562 - 569

    

32. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety

    • Vincenzo Gianturco
    • Giovanni Troisi
    • Vincenzo Marigliano

    Original Article 03 July 2012 Pages: 570 - 576

    

33. The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH)

    • Eiji Kakazu
    • Yasuteru Kondo
    • Tooru Shimosegawa

    Original Article 14 August 2012 Pages: 577 - 585

    

34. Insulin resistance, inflammation, and nonalcoholic fatty liver disease in non-obese adults without metabolic syndrome components

    • Seonah Kim
    • Jaekyung Choi
    • Mina Kim

    Original Article 29 November 2012 Pages: 586 - 591

35. The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients

    • Meredith A. Borman
    • Farah Ladak
    • Robert P. Myers

    Original Article 29 September 2012 Pages: 592 - 599

    

36. Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative

    • Jason J. Schwartz
    • Lyska Emerson
    • Mary Rinella

    Original Article 19 February 2013 Pages: 600 - 609

    

37. Fatty liver score and 15-year incidence of type 2 diabetes

    • Anna Kotronen
    • Maarit A. Laaksonen
    • Paul Knekt

    Original Article 12 March 2013 Pages: 610 - 621

    

38. Nitric oxide and prostaglandin as mediators in the pathogenesis of hyperkinetic circulatory state in a model of endotoxemia-induced portal hypertension

    • Moattar Raza Rizvi
    • Mohammad Tauseef
    • Shiv Kumar Sarin

    Original Article 02 September 2012 Pages: 622 - 635

    

39. Percutaneous transhepatic variceal embolization with cyanoacrylate vs. transjugular intrahepatic portal systematic shunt for esophageal variceal bleeding

    • Xiangguo Tian
    • Yongjun Shi
    • Chunqing Zhang

    Original Article 13 March 2013 Pages: 636 - 644

    

40. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma

    • Yun-Hsuan Lee
    • Chia-Yang Hsu
    • Shou-Dong Lee

    Original Article 17 May 2012 Pages: 645 - 654

    

41. The expression of transporter OATP2/OATP8 decreases in undetectable hepatocellular carcinoma by Gd-EOB-MRI in the explanted cirrhotic liver

    • Masaaki Hidaka
    • Mitsuhisa Takatsuki
    • Susumu Eguchi

    Original Article 24 June 2012 Pages: 655 - 661

    

42. Diffusion-weighted imaging of hepatocellular carcinoma for predicting early recurrence and survival after hepatectomy

    • Ali Muhi
    • Tomoaki Ichikawa
    • Tsutomu Araki

    Original Article 22 June 2012 Pages: 662 - 668

    

43. p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis

    • Shuting Jia
    • Wenru Tang
    • Ying Luo

    Original Article 03 August 2012 Pages: 669 - 675

    

44. Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?

    • Tsung-Hsing Hung
    • Chen-Chi Tsai
    • Han-Chieh Lin

    Original Article 27 July 2012 Pages: 676 - 682

    

45. SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV

    • Kazuhiro Hamaoka
    • Sumiko Nagoshi
    • Satoshi Mochida

    Original Article 06 October 2012 Pages: 683 - 692

    

46. Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan

    • Chin-Hsiao Tseng

    Original Article 06 October 2012 Pages: 693 - 702

    

47. Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma

    • Sadahisa Ogasawara
    • Fumihiko Kanai
    • Osamu Yokosuka

    Original Article 12 February 2013 Pages: 703 - 713

    

48. Changing etiology of liver failure in 3,916 patients from northern China: a 10-year survey

    • Shaoli You
    • Yihui Rong
    • Shaojie Xin

    Original Article 07 February 2013 Pages: 714 - 720

    

49. Cell-free DNA as a potential marker to predict carbon tetrachloride-induced acute liver injury in rats

    • Benjamin Fredrick Gruenbaum
    • Matthew Boyko
    • Alexander Zlotnik

    Original Article 22 November 2012 Pages: 721 - 727

    

50. Short- and long-term outcomes of third liver transplantation at single centre

    • Hideya Kamei
    • Mamoun Al-Basheer
    • Douglas Quan

    Original Article 14 March 2012 Pages: 728 - 733